Complete Management and Medications for Pneumonia in Adults and Children

Adults – Outpatient Management

Previously Healthy Adults (No Comorbidities)

Amoxicillin 1 g orally three times daily for 5–7 days is the preferred first-line therapy because it retains activity against 90–95% of Streptococcus pneumoniae isolates, including many penicillin-resistant strains, and provides superior pneumococcal coverage compared with oral cephalosporins. 12

Alternative: Doxycycline 100 mg orally twice daily for 5–7 days offers coverage of both typical bacterial pathogens and atypical organisms (Mycoplasma, Chlamydophila, Legionella). 12
Macrolide monotherapy (azithromycin 500 mg day 1, then 250 mg daily; or clarithromycin 500 mg twice daily) should be used only in areas where pneumococcal macrolide resistance is documented <25%; in most U.S. regions resistance is 20–30%, making macrolides unsafe as first-line agents. 123
Avoid oral cephalosporins (cefuroxime, cefpodoxime) as first-line agents—they have inferior in-vitro activity against S. pneumoniae, lack atypical coverage, and show no demonstrated clinical superiority. 12

Adults With Comorbidities (COPD, Diabetes, Chronic Organ Disease, Recent Antibiotic Use)

Combination therapy is mandatory for patients with comorbidities or recent antibiotic exposure within 90 days. 12

Preferred regimen: Amoxicillin-clavulanate 875/125 mg orally twice daily plus azithromycin (500 mg day 1, then 250 mg daily for days 2–5), providing comprehensive coverage of typical and atypical pathogens with 91.5% favorable clinical outcomes. 12
Alternative β-lactams: Cefpodoxime or cefuroxime must be combined with a macrolide or doxycycline to achieve similar spectrum. 12
Respiratory fluoroquinolone monotherapy: Levofloxacin 750 mg daily or moxifloxacin 400 mg daily for 5–7 days is reserved for β-lactam-allergic patients or when macrolides are contraindicated, given FDA warnings about serious adverse events (tendon rupture, peripheral neuropathy, aortic dissection). 123

Severity Assessment and Hospitalization Criteria

Use PSI (Pneumonia Severity Index) or CURB-65 scores combined with clinical judgment to determine site of care. 42
PSI classes I–III: Outpatient management appropriate unless unstable comorbidities present. 42
PSI classes IV–V or CURB-65 ≥2: Hospital admission recommended. 42
Absolute indications for admission: Hypotension (SBP <90 mmHg), respiratory rate >30/min, oxygen saturation <92% on room air, inability to maintain oral intake, altered mental status, or multilobar infiltrates. 42

Outpatient Monitoring and Follow-Up

Clinical review at 48 hours (or sooner if symptoms worsen) to assess response, oral intake, and need for escalation. 42
Treatment failure indicators: No improvement by day 2–3, development of respiratory distress, inability to tolerate oral antibiotics, or new complications such as pleural effusion. 42
Escalation strategy: If amoxicillin monotherapy fails, add or substitute a macrolide; if combination therapy fails, switch to a respiratory fluoroquinolone. 42
Routine follow-up at 6 weeks for all patients; obtain chest radiograph only if symptoms persist, physical signs remain, or high risk for underlying malignancy (smokers >50 years). 42

Adults – Inpatient Management (Non-ICU)

Standard Empiric Regimen

Two equally effective regimens exist with strong recommendations and high-quality evidence: 12

β-lactam plus macrolide: Ceftriaxone 1–2 g IV daily plus azithromycin 500 mg IV or orally daily, providing coverage for typical pathogens (S. pneumoniae, H. influenzae, M. catarrhalis) and atypical organisms. 125
Respiratory fluoroquinolone monotherapy: Levofloxacin 750 mg IV daily or moxifloxacin 400 mg IV daily, associated with fewer clinical failures and treatment discontinuations compared with β-lactam/macrolide combinations. 12

Critical Timing Considerations

Administer the first antibiotic dose in the emergency department immediately upon diagnosis—delays beyond 8 hours increase 30-day mortality by 20–30%. 1265
Obtain blood cultures and sputum Gram stain/culture before the first antibiotic dose to enable pathogen-directed therapy and safe de-escalation. 12

Transition to Oral Therapy

Switch from IV to oral antibiotics when all clinical stability criteria are met: hemodynamically stable (SBP ≥90 mmHg, HR ≤100 bpm), clinically improving, afebrile for 48–72 hours, respiratory rate ≤24/min, SpO₂ ≥90% on room air, able to take oral medication—typically by hospital day 2–3. 12
Oral step-down options: Amoxicillin 1 g three times daily plus azithromycin 500 mg daily, or continue azithromycin alone after 2–3 days of IV β-lactam coverage. 12

Duration of Therapy

Minimum duration: 5 days, continuing until the patient is afebrile for 48–72 hours with ≤1 sign of clinical instability. 125
Typical duration for uncomplicated CAP: 5–7 days. 125
Extended duration (14–21 days) required only for Legionella pneumophila, Staphylococcus aureus, or Gram-negative enteric bacilli infections. 12

Monitoring and Reassessment

Monitor vital signs (temperature, respiratory rate, pulse, blood pressure, oxygen saturation) at least twice daily to detect early deterioration. 42
If no clinical improvement by day 2–3: Obtain repeat chest radiograph, inflammatory markers (CRP, white blood cell count), and additional microbiologic specimens to evaluate for complications such as pleural effusion, empyema, or resistant organisms. 42

Adults – ICU Management (Severe CAP)

Mandatory Combination Therapy

Combination therapy is mandatory for all ICU patients—β-lactam monotherapy is associated with significantly higher mortality in critically ill patients with bacteremic pneumococcal pneumonia. 127

Preferred ICU regimen: Ceftriaxone 2 g IV daily (or cefotaxime 1–2 g IV every 8 hours or ampicillin-sulbactam 3 g IV every 6 hours) plus azithromycin 500 mg IV daily or a respiratory fluoroquinolone (levofloxacin 750 mg IV daily or moxifloxacin 400 mg IV daily). 126
Penicillin-allergic ICU patients: Aztreonam 2 g IV every 8 hours plus levofloxacin 750 mg IV daily. 12

ICU Admission Criteria

Major criteria (any one mandates ICU): Septic shock requiring vasopressors or respiratory failure requiring mechanical ventilation. 12
Minor criteria (≥3 mandate ICU): Confusion, respiratory rate ≥30/min, systolic BP <90 mmHg, multilobar infiltrates, PaO₂/FiO₂ <250, uremia (BUN ≥20 mg/dL), leukopenia, thrombocytopenia, hypothermia, or need for aggressive fluid resuscitation. 12

Supportive Care in ICU

Oxygen therapy: Maintain PaO₂ >8 kPa (60 mmHg) and SpO₂ >92%; high-flow oxygen is safe in uncomplicated pneumonia. 42
Fluid management: Assess for volume depletion and give IV fluids as needed; in septic shock, administer aggressive crystalloid bolus of 30 mL/kg within the first 3 hours. 12
Vasopressor support: If SBP remains <90 mmHg after initial fluid resuscitation, start norepinephrine (preferred vasopressor). 12
Corticosteroids: Systemic corticosteroid administration within 24 hours of development of severe CAP may reduce 28-day mortality. 57

Special Pathogen Coverage (Risk-Factor Based)

Antipseudomonal Therapy

Add antipseudomonal agents only when documented risk factors are present: structural lung disease (bronchiectasis, cystic fibrosis), recent hospitalization with IV antibiotics within 90 days, prior respiratory isolation of Pseudomonas aeruginosa, or chronic broad-spectrum antibiotic exposure (≥7 days in the past month). 123

Regimen: Antipseudomonal β-lactam (piperacillin-tazobactam 4.5 g IV every 6 hours or cefepime 2 g IV every 8 hours or carbapenem) plus ciprofloxacin 400 mg IV every 8 hours or levofloxacin 750 mg IV daily plus an aminoglycoside (gentamicin or tobramycin 5–7 mg/kg IV daily) for dual antipseudomonal coverage. 123

MRSA Coverage

Add MRSA agents only when documented risk factors are present: prior MRSA infection/colonization, recent hospitalization with IV antibiotics, post-influenza pneumonia, or cavitary infiltrates on imaging. 123

Regimen: Vancomycin 15 mg/kg IV every 8–12 hours (target trough 15–20 µg/mL) or linezolid 600 mg IV every 12 hours, added to the base CAP regimen. 123

Children – Outpatient Management

Severity Assessment and Admission Criteria

Pulse oximetry should be performed in all children with pneumonia and suspected hypoxemia—the presence of hypoxemia should guide decisions regarding site of care and further diagnostic testing. 4
Routine chest radiographs are not necessary for confirmation of suspected CAP in patients well enough to be treated in the outpatient setting. 4
Chest radiographs (posteroanterior and lateral) should be obtained in patients with suspected or documented hypoxemia or significant respiratory distress, and in those with failed initial antibiotic therapy to verify complications. 4

Empiric Antibiotic Selection

For fully immunized children with CAP managed as outpatients: Amoxicillin is the preferred first-line agent, with macrolide coverage added for school-aged children and adolescents with clinical features suggesting atypical pathogens (Mycoplasma pneumoniae, Chlamydophila pneumoniae). 48
Macrolide monotherapy (azithromycin or clarithromycin) may be considered for children ≥5 years with suspected atypical pneumonia, but should not be used as first-line in younger children. 48

Monitoring and Follow-Up

Repeated chest radiographs are not routinely required in children who recover uneventfully from an episode of CAP. 4
Repeated chest radiographs should be obtained in children who fail to demonstrate clinical improvement and in those who have progressive symptoms or clinical deterioration within 48–72 hours after initiation of antibiotic therapy. 4

Children – Inpatient Management

Diagnostic Work-Up

Chest radiographs (posteroanterior and lateral) should be obtained in all patients hospitalized for management of CAP to document the presence, size, and character of parenchymal infiltrates and identify complications. 4
Acute-phase reactants (ESR, CRP, procalcitonin) may be used in conjunction with clinical findings to assess response to therapy in patients with more serious disease, such as those requiring hospitalization or those with pneumonia-associated complications. 4

Severity Criteria for ICU Admission

Consider ICU care or continuous cardiorespiratory monitoring for children with ≥1 major or ≥2 minor criteria: 4

Major criteria: Invasive mechanical ventilation, fluid-refractory shock, acute need for noninvasive positive pressure ventilation (NIPPV), hypoxemia requiring FiO₂ greater than inspired concentration or flow feasible in general care area.
Minor criteria: Respiratory rate higher than WHO classification for age, apnea, increased work of breathing (retractions, dyspnea, nasal flaring, grunting), PaO₂/FiO₂ ratio <250, multilobar infiltrates, PEWS score >6, altered mental status, hypotension, presence of effusion, comorbid conditions (HgbSS, immunosuppression, immunodeficiency), unexplained metabolic acidosis.

Empiric Antibiotic Therapy

For hospitalized children without severe disease: Ampicillin or penicillin G is preferred for typical bacterial pneumonia, with macrolide added if atypical pathogens are suspected. 48
For severe CAP requiring ICU admission: Combination therapy with a third-generation cephalosporin (ceftriaxone or cefotaxime) plus a macrolide (azithromycin or clarithromycin) is recommended. 48

Duration and Monitoring

Minimum duration: 5 days for uncomplicated CAP, with treatment continuing until clinical stability is achieved. 48
Routine daily chest radiography is not recommended in children with pneumonia complicated by parapneumonic effusion after chest tube placement or VATS, if they remain clinically stable. 4

Critical Pitfalls to Avoid (Adults and Children)

Do not delay antibiotic administration—initiating therapy immediately upon diagnosis prevents a 20–30% increase in 30-day mortality associated with delays >8 hours in hospitalized patients. 126
Do not use macrolide monotherapy in hospitalized patients—it fails to cover typical pathogens such as S. pneumoniae and leads to treatment failure. 12
Do not use macrolide monotherapy in outpatients with comorbidities or in regions with macrolide resistance >25%—resistant strains markedly increase breakthrough bacteremia. 123
Do not add broad-spectrum antipseudomonal or MRSA agents routinely—restrict to patients with documented risk factors to avoid unnecessary resistance, adverse effects, and cost. 123
Do not extend therapy beyond 7–8 days in responding patients without specific indications—longer courses increase antimicrobial resistance without improving outcomes. 12
Obtain blood and sputum cultures before starting antibiotics in all hospitalized patients to enable pathogen-directed therapy and safe de-escalation. 12

Prevention and Vaccination

Pneumococcal vaccination: Offer 20-valent pneumococcal conjugate vaccine alone or 15-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal polysaccharide vaccine one year later to all adults ≥65 years and those 19–64 with underlying conditions. 123
Annual influenza vaccination: Recommend for all patients, especially those with chronic medical illnesses. 123
COVID-19 vaccination: Recommend for all adults per CDC guidelines. 3
Smoking cessation counseling: Provide to all current smokers. 12

What is the comprehensive management plan—including severity assessment, supportive care, and specific antibiotic regimens—for community‑acquired pneumonia in adults and children in outpatient, inpatient, and intensive care settings?

Help us tailor your experience